Fate Therapeutics, Inc.
FATE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $41 | $41 | $45 | $36 |
| Short-Term Investments | $175 | $182 | $196 | $243 |
| Receivables | $1 | $1 | $2 | $4 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $6 | $5 | $9 |
| Total Curr. Assets | $221 | $230 | $248 | $292 |
| Property Plant & Equip (Net) | $102 | $105 | $108 | $111 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $10 | $26 | $32 | $28 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $10 | $10 | $10 | $10 |
| Total NC Assets | $122 | $141 | $150 | $149 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $344 | $372 | $399 | $441 |
| Liabilities | – | – | – | – |
| Payables | $4 | $4 | $4 | $9 |
| Short-Term Debt | $5 | $6 | $7 | $7 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $20 | $19 | $17 | $21 |
| Total Curr. Liab. | $28 | $29 | $28 | $39 |
| LT Debt | $74 | $76 | $77 | $78 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $7 | $6 | $5 | $6 |
| Total NC Liab. | $81 | $82 | $82 | $83 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $79 | $81 | $83 | $85 |
| Total Liabilities | $110 | $110 | $110 | $122 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,502 | -$1,470 | -$1,436 | -$1,398 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $1,736 | $1,731 | $1,724 | $1,716 |
| Total Equity | $234 | $261 | $288 | $319 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $344 | $372 | $399 | $441 |
| Net Debt | $39 | $40 | $38 | $49 |